Fludarabine in the Treatment of Refractory Chronic Inflammatory Demyelinating Neuropathies

Journal of Clinical Neuromuscular Disease

Volumn 17, Issue 1, 2015, Pages 1-5

  Leitch, Megan M ^a   Sherman, William H ^b   Brannagan, Thomas H ^c  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Howard Hughes Medical Institute   (United States)

^c NEUROLOGICAL INSTITUTE   (United States)

Author keywords

drug resistance; fludarabine; Inflammatory neuropathy; rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; GLYCOPROTEIN; IMMUNOGLOBULIN M; MYELIN; RITUXIMAB; ANTINEOPLASTIC AGENT; MYELIN ASSOCIATED GLYCOPROTEIN; VIDARABINE;

ADULT; AGED; ARTICLE; CHRONIC INFLAMMATION; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; CONSTIPATION; DEMYELINATING NEUROPATHY; EXHAUSTION; FEMALE; FUNCTIONAL STATUS; HUMAN; IRRITABILITY; MALE; MIDDLE AGED; PRIORITY JOURNAL; REMISSION; ANALOGS AND DERIVATIVES; BLOOD; CHRONIC LYMPHATIC LEUKEMIA; IMMUNOLOGY; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

AGED; ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOGLOBULIN M; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MYELIN-ASSOCIATED GLYCOPROTEIN; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; VIDARABINE;

EID: 84941208620     PISSN: 15220443     EISSN: 15371611     Source Type: Journal    
DOI: 10.1097/CND.0000000000000083     Document Type: Article

References (19)

1. Dyck PJ, O'Brien PC, Oviatt KF, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol. 1982;11:136-141.
2. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol. 2008;7:136-144.
3. Hahn AF, Bolton CF, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, crossover study. Brain. 1996;119:1055-1066.
4. Gorson KC, Allam G, Ropper AH. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology. 1997;48:321-328.
5. Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebocontrolled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009;65:286-293.
6. Brunton LL, Parker KL, Lato JS. Goodman & Gilmans's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-HIll; 2005.
7. Keating MJ, O'Brien S, Plunkett W, et al. Fludarabine phosphate: a new active agent in hematologic malignancies. Semin Hematol. 1994;31:28-39.
8. Rodriguez G. Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma. Invest New Drugs. 1994;12:75-92.
9. Gassner FJ, Weiss L, Geisberger R, et al. Fludarabine modulates composition and function of the T cell pool in patients with chronic lymphocytic leukaemia. Cancer Immunol Immunother. 2011;60:75-85.
10. Sherman WH. Fludarabine for IgM Antibodymediated neuropathies. Ann Neurol. 1994;36: 326-327.
11. Wilson HC, Lunn MP, Schey S, et al. Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. J Neurol Neurosurg Psychiatry. 1999;66: 575-580.
12. Gruson B, Ghomari K, Beaumont M, et al. Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy. J Peripher Nerv Syst. 2011;16:180-185.
13. Koya J, Iwata A, Nakamura F, et al. Fludarabine may overcome resistance to rituximab in IgM-related neuropathy. J Neurol Sci. 2012;315:150-152.
14. Niermeijer JM, Eurelings M, Lokhorst H, et al. Neurologic and hematologic response to fludarabine treatment in IgM MGUS polyneuropathy. Neurology. 2006;67:2076-2079.
15. Leitch MM, Sherman WH, Brannagan TH III. Distal acquired demyelinating symmetric polyneuropathy progressing to classic chronic inflammatory demyelinating polyneuropathy and response to fludarabine and cyclophosphamide. Muscle Nerve. 2013; 47:292-296.
16. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDECC2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90:2188-2195.
17. Brannagan TH III, Pradhan A, Heiman-Patterson T, et al. High-dose cyclophosphamide without stemcell rescue for refractory CIDP. Neurology. 2002; 58:1856-1858.
18. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107: 885-891.
19. Ysebaert L, Gross E, Kuhlein E, et al. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy. Leukemia. 2010;24:1310-1316.